bioAffinity Technologies, Inc.
BIAFNasdaq
$0.70
↓ -1.1%Jul 17 close · end-of-day
Price
1Y↓ -92.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.2M
Enterprise Value
$64,590.98
P/E
—
P/S
0.6
P/B
0.9
EV/EBITDA
—
PEG
—
FCF Yield
-345.5%
Dividend Yield
—
Revenue (TTM)
$5.7M
Net Income (TTM)
-$15.9M
Free Cash Flow (TTM)
-$10.9M
Gross Margin
—
Operating Margin
-204.3%
Net Margin
-280.6%
ROE
-433.7%
ROIC
-1622.4%
Debt / Equity
—
Net Cash
$3.1M
Return 1Y
-92.9%
Company profile
bioAffinity Technologies, Inc. is a privately held company incorporated in Delaware addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. Our principal executive office is located at 22211 West Interstate 10, Suite 1206, San Antonio, Texas 78257, and our telephone number at that address is (210) 698-5334. Our laboratory diagnostic and therapeutic research is conducted at The Harvey Sandler Cancer Research Laboratories, which is located at Science Research Laboratories, Suite 1.424, University of Texas at San Antonio, San Antonio, Texas.
- CEO
- Maria Zannes
- Sector
- Services
- Industry
- Business Services
- Employees
- 10
- Headquarters
- Texas
- Website
- bioaffinitytech.com
Earnings
BIAF Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.4M↓ -27.1%
Diluted EPS-$0.81↓ -83.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $6.9M | $7.9M | $9.4M | $6.2M |
| Gross profit | — | $4,336.00 | — | — | — |
| Operating income | -$2.2M | -$4.0M | -$8.0M | -$9.0M | -$10.6M |
| Net income | -$6.3M | -$8.2M | -$7.9M | -$9.0M | -$14.9M |
| Diluted EPS | — | -$1.81 | -$0.91 | -$22.50 | -$8.66 |
| Operating cash flow | -$2.0M | -$4.1M | -$6.0M | -$7.3M | -$9.3M |
| Free cash flow | — | -$4.3M | -$6.1M | -$7.3M | -$9.4M |
| Gross margin | — | 0.1% | — | — | — |
| Operating margin | — | -58.1% | -100.9% | -95.6% | -171.6% |
| Net margin | — | -118.2% | -100.5% | -96.6% | -242.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.4M | $2.2M | $1.9M | $1.3M | $1.4M | $1.6M | $1.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.1M | -$2.0M | -$2.9M | -$2.6M | -$2.5M | -$2.3M | -$3.1M | -$3.6M |
| Net income | -$2.1M | -$2.0M | -$3.0M | -$2.7M | -$4.1M | -$5.1M | -$3.1M | -$3.6M |
| Diluted EPS | -$0.19 | -$4.84 | -$17.27 | -$4.80 | -$0.17 | -$4.74 | $1.05 | -$0.81 |
| Operating cash flow | -$1.5M | -$1.7M | -$1.7M | -$1.6M | -$2.6M | -$2.5M | -$2.6M | -$3.2M |
| Free cash flow | -$1.6M | -$1.7M | -$1.7M | -$1.7M | -$2.7M | -$2.5M | -$2.6M | -$3.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -87.1% | -84.0% | -133.5% | -141.7% | -198.2% | -158.6% | -196.9% | -267.6% |
| Net margin | -88.0% | -85.1% | -134.4% | -143.5% | -319.9% | -349.3% | -197.0% | -268.6% |
Company news
Jul 9, 2026
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.